- Trial phase
- Phase 1 completed; advancing to Phase 2
- Time to market
- XEN1120 has completed Phase 1 and is advancing to Phase 2 proof-of-concept studies expected in H1 2027. Even if Phase 2 succeeds, the drug would still need Phase 3 trials and FDA review, putting potential approval several years away (likely 2029-2031 at the earliest).
- Why 3/10
- XEN1120 has no hard binary catalyst (PDUFA or pivotal readout) scheduled within the next ~12 months. The next milestone is the initiation of Phase 2 proof-of-concept studies in acute pain, expected in H1 2027, which is a non-binary operational update. XEN1120 is an early-stage asset at a company whose primary value driver is azetukalner, so even positive Phase 2 news would have limited impact on the stock.
Watch for the initiation of Phase 2 proof-of-concept studies for XEN1120 in acute pain, expected in H1 2027. The more immediate catalysts for Xenon stock are the December 2026 X-NOVA2 MDD topline readout for azetukalner and the FDA's review of the azetukalner NDA for focal seizures. XEN1120 is too early-stage to drive material share-price moves on its own.
Price Chart
Executive Summary
XEN1120 is an investigational Kv7 potassium channel opener being developed by Xenon Pharmaceuticals (XENE, Nasdaq) as a non-opioid treatment for acute pain. On October 29, 2026, Xenon announced positive Phase 1 results at the IASP 2026 conference, showing XEN1120 achieved plasma levels predictive of analgesic effects and was generally well-tolerated. The company plans to advance XEN1120 (alongside its NaV1.7 pain candidate XEN1701) to Phase 2 proof-of-concept studies in acute pain, expected to begin in the first half of 2027. XEN1120 is an early-stage pipeline asset; Xenon's primary value driver is azetukalner (XEN1101), a Kv7 opener with an NDA submitted for focal seizures and a Phase 3 depression readout expected in December 2026. Xenon held $1.15B in cash as of September 30, 2026, funding operations into 2029.
How It Works
XEN1120 is a Kv7 potassium channel opener. Kv7 channels act like 'brakes' on nerve cells: opening them stabilizes the electrical activity of neurons and reduces excessive firing that transmits pain signals. This makes XEN1120 a non-opioid approach to treating acute pain, avoiding the addiction and respiratory-depression risks of opioids.
Trial Status
Positive Phase 1 results announced October 29, 2026 at IASP 2026. Phase 1 achieved target plasma levels predictive of analgesic effects with good tolerability. The company is advancing XEN1120 to Phase 2 proof-of-concept studies in acute pain, expected to begin in H1 2027.
The Two-Sided Case
Upcoming Catalysts
- Initiation of Phase 2 proof-of-concept studies for XEN1120 in acute pain, expected H1 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Xenon Pharmaceuticals Inc. 8-K XENE ·Originating report